Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation

Annals of Hematology

Volumn 95, Issue 4, 2016, Pages 557-562

  Schwaab, Juliana ^a   Jawhar, Mohamad ^a   Naumann, Nicole ^a   Schmitt Graeff, Annette ^b   Fabarius, Alice ^a   Horny, Hans Peter ^c   Cross, Nicholas C P ^d,e   Hofmann, Wolf Karsten ^a   Reiter, Andreas ^a   Metzgeroth, Georgia ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Bone marrow histology; FIP1L1 PDGFRA; Hypereosinophilia; Misdiagnosis

Indexed keywords

CORTICOSTEROID; IMATINIB; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EOSINOPHILIA; FEMALE; FIP1L1 PDGFRA GENE; FUSION GENE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MAST CELL; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS; TREATMENT RESPONSE; ADOLESCENT; BIOPSY; BONE MARROW; CASE REPORT; GENETICS; MIDDLE AGED; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; STANDARDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BONE MARROW; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84959498230     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-016-2598-x     Document Type: Article

References (14)

1. Metzgeroth G, Schwaab J, Gosenca D, Fabarius A, Haferlach C, Hochhaus A, Cross NC, Hofmann WK, Reiter A (2013) Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia 27(11):2254–2256
2. Valent P, Klion AD, Rosenwasser LJ, Arock M, Bochner BS, Butterfield JH, Gotlib J, Haferlach T, Hellmann A, Horny HP, Leiferman KM, Metzgeroth G, Matsumoto K, Reiter A, Roufosse F, Rothenberg ME, Simon HU, Sotlar K, Vandenberghe P, Weller PF, Gleich GJ (2012) ICON: eosinophil disorders. The World Allergy Organization journal 5(12):174–181
3. Walz C, Score J, Mix J, Cilloni D, Roche-Lestienne C, Yeh RF, Wiemels JL, Ottaviani E, Erben P, Hochhaus A, Baccarani M, Grimwade D, Preudhomme C, Apperley J, Martinelli G, Saglio G, Cross NC, Reiter A (2009) The molecular anatomy of the FIP1L1-PDGFRA fusion gene. Leukemia 23(2):271–278
4. Walz C, Cross NC, Van Etten RA, Reiter A (2008) Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia 22(7):1320–1334
5. Walz C, Metzgeroth G, Haferlach C, Schmitt-Graeff A, Fabarius A, Hagen V, Prummer O, Rauh S, Hehlmann R, Hochhaus A, Cross NC, Reiter A (2007) Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 92(2):163–169
6. Walz C, Chase A, Schoch C, Weisser A, Schlegel F, Hochhaus A, Fuchs R, Schmitt-Graff A, Hehlmann R, Cross NC, Reiter A (2005) The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia 19(6):1005–1009
7. Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, Tapper W, Score J, Waghorn K, Naumann N, Jawhar M, Fabarius A, Hofmann WK, Cross NC, Reiter A (2015) Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol 94(2):233–238
8. Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NC, Hehlmann R, Hochhaus A, Reiter A (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 143(5):707–715
9. Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C, Klippstein T, Hochhaus A, Cross NC, Hofmann WK, Reiter A (2012) Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 26(1):162–164
10. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937–951
11. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348(13):1201–1214
12. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB (2003) Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101(12):4660–4666
13. Valent P, Sperr WR, Sotlar K, Reiter A, Akin C, Gotlib J, Horny HP, Arock M (2014) The serum tryptase test: an emerging robust biomarker in clinical hematology. Expert Rev Hematol 7(5):683–690
14. Madelung AB, Bondo H, Stamp I, Loevgreen P, Nielsen SL, Falensteen A, Knudsen H, Ehinger M, Dahl-Sorensen R, Mortensen NB, Svendsen KD, Lange T, Ralfkiaer E, Nielsen K, Hasselbalch HC, Thiele J (2013) World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations—the Danish experience. Am J Hematol 88(12):1012–1016